Understanding how certain cancers respond to Notch inhibitors
Official title: Epigenetic Mechanisms Underpinning Mantle Cell Lymphoma Sensitivity and Resistance to Notch Inhibitors
Funded at University of Pennsylvania · NIH-11082432 · Data updated 2026-11-12
This study is looking into why some people with mantle cell lymphoma and chronic lymphocytic leukemia benefit from Notch inhibitors while others don’t, hoping to find clues in their genes that could help create better treatments for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | April 1, 2022 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $418,291 |
| NIH project number | 5R01CA248041-04 |
| Project ID | NIH-11082432 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with mantle cell lymphoma or chronic lymphocytic leukemia, particularly those with Notch mutations.
✕Less likely to help
Patients without mantle cell lymphoma or chronic lymphocytic leukemia, or those who do not have Notch mutations, may not benefit from this research.
What this research studies
This research investigates the mechanisms that determine why some patients with mantle cell lymphoma and chronic lymphocytic leukemia respond to Notch inhibitors while others do not. By examining the genetic and epigenetic factors involved, the study aims to identify how Notch mutations influence treatment outcomes. The researchers will utilize advanced techniques such as functional genomics and genome engineering to analyze cancer cells at a detailed level. This approach seeks to uncover the underlying biology that could lead to more effective therapies for patients with these types of blood cancers.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with mantle cell lymphoma and chronic lymphocytic leukemia.
How similar studies have gone: Previous research has shown promise in targeting Notch pathways in other cancers, suggesting potential for success in this area as well.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Faryabi, Robert Babak — University of Pennsylvania
- Study coordinator: Faryabi, Robert Babak
Related research
Other NIH-funded projects on the same topics.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Duvelisib for preventing cytokine release syndrome in CAR T-cell therapy patients
A study tests whether taking duvelisib before CAR T-cell therapy can prevent dangerous inflammatory reactions in patients with large B-cell or mantle cell lymphoma.
-
ERBB signaling and ibrutinib resistance in mantle cell lymphoma
A short, patient-friendly look at how scientists study why some mantle cell lymphoma patients stop responding to ibrutinib and how ERBB signaling might be involved.
-
Why some mantle cell lymphomas respond to Notch-blocking drugs
Researchers are looking at DNA regulatory changes to understand why some mantle cell lymphomas respond to drugs that block Notch while others resist them.
-
Preventing a serious side effect of CAR T-cell therapy for lymphoma
This project is testing a new medication called Duvelisib to help prevent a serious immune reaction called cytokine release syndrome in people with large cell or mantle cell lymphoma who are receiving CAR T-cell therapy.
-
Understanding CEACAM1 in Mantle Cell Lymphoma and New Treatments
This research looks for new ways to treat mantle cell lymphoma, especially for patients whose current medications are not working well.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.